RiaSTAP (Fibrinogen concentrate [human]) for Hemophilia

Overview
RiaSTAP is approved by the Food and Drug Administration (FDA) to treat acute bleeding episodes in people with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. The technical name of RiaSTAP is Fibrinogen concentrate (human).

RiaSTAP is a clotting factor. Clotting factors work by supplying proteins missing in people with certain bleeding disorders.

How do I take it?
Prescribing information states that RiaSTAP is given as an intravenous injection.

RiaSTAP comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for RiaSTAP lists common side effects including headache and fever.

Rare but serious side effects listed for RiaSTAP include anaphylactic (severe allergic) reactions and thrombotic episodes in which blood clots form in blood vessels, leading to heart attack, pulmonary embolism, or deep vein thrombosis.

For more details about this treatment, visit:

RiaSTAP - CSL Behring
http://www.riastap.com/

Treatment of Hemophilia - Hemophilia Federation of America
http://www.hemophiliafed.org/bleeding-disorders...